Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taladegib - Eli Lilly and Company

Drug Profile

Taladegib - Eli Lilly and Company

Alternative Names: LY-2940680

Latest Information Update: 01 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Ignyta
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Phthalazines; Piperidines; Pyrazoles; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Oesophageal cancer; Small cell lung cancer
  • Preclinical Basal cell cancer
  • No development reported Cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Capsule)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top